Skip to main content
. 2021 May 10;100(9):2325–2337. doi: 10.1007/s00277-021-04534-8

Fig. 1.

Fig. 1

Regimen composition for LOTs ≥ 2. aOther includes bendamustine, doxorubicin, etoposide, melphalan, panobinostat, thalidomide, and vincristine. bOther includes doxorubicin, melphalan, panobinostat, and thalidomide. cOther includes cyclophosphamide, ixazomib, melphalan, thalidomide, and panobinostat. dOther includes bendamustine, melphalan, and thalidomide. Each component of “other” contributed < 3.5% to the total within each group. Key: C, cyclophosphamide; d, dexamethasone; D, daratumumab; I, ixazomib; K, carfilzomib; V, bortezomib; P, pomalidomide; R, lenalidomide